These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26933862)

  • 1. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.
    Ruan J; Leonard JP
    N Engl J Med; 2016 Feb; 374(8):793. PubMed ID: 26933862
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.
    Tsuda K; Tanimoto T; Komatsu T
    N Engl J Med; 2016 Feb; 374(8):792-3. PubMed ID: 26933863
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
    Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
    N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi- center phase II study of lenalidomide plus rituximab.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):17-8. PubMed ID: 24870878
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous transplantation and management of younger patients with mantle cell lymphoma.
    Geisler CH
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial.
    Laurell A; Kolstad A; Jerkeman M; Räty R; Geisler CH
    Leuk Lymphoma; 2014 May; 55(5):1206-8. PubMed ID: 23876100
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of older patients with mantle-cell lymphoma.
    Takahashi Y; Mori J; Tanimoto T
    N Engl J Med; 2012 Nov; 367(18):1765; author reply 1765-6. PubMed ID: 23113500
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
    Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
    Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
    Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
    Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
    [No Abstract]   [Full Text] [Related]  

  • 13. New combinations for mantle cell lymphoma: concerted action needed.
    Hess G
    Lancet Oncol; 2011 Apr; 12(4):315-6. PubMed ID: 21440504
    [No Abstract]   [Full Text] [Related]  

  • 14. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
    Chong EA; Ahmadi T; Aqui NA; Svoboda J; Nasta SD; Mato AR; Walsh KM; Schuster SJ
    Clin Cancer Res; 2015 Apr; 21(8):1835-42. PubMed ID: 25632047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Epstein-Peterson ZD; Drill E; Aypar U; Batlevi CL; Caron P; Dogan A; Drullinsky P; Gerecitano J; Hamlin PA; Ho C; Jacob A; Joseph A; Laraque L; Matasar MJ; Moskowitz AJ; Moskowitz CH; Mullins C; Owens C; Salles G; Schöder H; Straus DJ; Younes A; Zelenetz AD; Kumar A
    Haematologica; 2024 Aug; 109(8):2749-2752. PubMed ID: 39087412
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
    Cheah CY; Nastoupil LJ; Neelapu SS; Forbes SG; Oki Y; Fowler NH
    Blood; 2015 May; 125(21):3357-9. PubMed ID: 25999447
    [No Abstract]   [Full Text] [Related]  

  • 20. [Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].
    Ota I; Katsura Y; Yoshida C; Yoshizawa K; Ohtani H; Sata T; Komeno T
    Rinsho Ketsueki; 2010 Dec; 51(12):1786-8. PubMed ID: 21258190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.